Results 101 to 110 of about 5,184,182 (156)

FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation. [PDF]

J Med Chem
Kumar A, Ali S, Shen Q, Zhou J.
europepmc   +1 more source

Aptamer-Based Heterobifunctional Targeted Degraders in Disease Treatment. [PDF]

Molecules
Liang X, Du M, Wang J, Lei X, Tian Y, Zhang X.   +5 more
europepmc   +1 more source

Knowledge mapping and bibliometric insights of scientific research on targeted protein degradation in oncology. [PDF]

J Cancer Res Clin Oncol
Sweileh MW.
europepmc   +1 more source

From undruggable to degradable: A deep learning-enabled framework for precision orthopaedic protein degradation. [PDF]

J Orthop Translat
Zhang L, Wang Y, Wang D, Ma J.
europepmc   +1 more source

Optimizing CRBN-ligands for optical targeted protein degradation. [PDF]

RSC Med Chem
Flores JA, DiNardi RG, Burslem GM, Cheng T, Trauner DH.   +4 more
europepmc   +1 more source

Molecular glue degraders versus PROTACs: a novel paradigm in targeted protein degradation. [PDF]

Ann Med Surg (Lond)
Tahir A, Khan SA, Imtiaz E, Qamar MA.
europepmc   +1 more source

A destination-driven framework for nanoparticle-enabled targeted protein degradation. [PDF]

Acta Pharm Sin B
Wang Y, Xia X, Xie S, Tong F, Liu W, Gao H.   +5 more
europepmc   +1 more source

Beyond canonical ADCP: integrating targeted protein degradation to overcome phagocytic resistance. [PDF]

J Transl Med
Zhang W, Jiang J, Sun Y, Yao Y.
europepmc   +1 more source

Drug Discovery of Allosteric Molecular Glue Degraders (aMGDs): Expanding the Landscape of Targeted Protein Degradation. [PDF]

J Med Chem
Xue Y, Ali S, Chen H, Zhou J.
europepmc   +1 more source

Targeted protein degradation for fetal hemoglobin induction: a new paradigm in β-hemoglobinopathy therapy. [PDF]

Biomark Res
Arji S, Shen Z, Welch S, ElMahdaoui F, Bahadur A, Lee E, Lee H, Wu SP, Konshina E, Ayubali B, Tenen D, Chai L, Liu J.   +12 more
europepmc   +1 more source